Euroseas Ltd. Announces Acquisition of a Vessel and the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Euroseas Ltd. Announces Acquisition of a Vessel and the Sale of One of Its Vessels for Scrap

MAROUSSI, ATHENS, GREECE--(Marketwired - Jun 18, 2013) - Euroseas Ltd., ( NASDAQ : ESEA ) an owner and operator of drybulk carriers and containerships and provider of seaborne transportation for dry bulk and containerized cargoes, announced today that it sold for scrap one of the oldest container vessels in its fleet, the M/V Anking, a 950 teu multipurpose vessel built in 1990 for approximately $3.7 million. The vessel will be delivered to her new owners by the end of June 2013.

Furthermore, the Company announced that it signed a memorandum of agreement to purchase the M/V Wehr Flottbek, a geared containership of 22,301 dwt and 1,738 teu built in 1999 for approximately $5.9 million. The vessel, to be renamed "Joanna", is expected to be delivered to the Company by the end of June 2013.

Aristides Pittas, Chairman and CEO of Euroseas, commented: "With containership prices having again dropped near their all-time low levels, we believe, it is an opportunity to renew our fleet at minimal capital cost. In that respect, we have sold for scrap our vessel M/V Anking, a 1990 built multipurpose vessel, and invested the proceeds along with an incremental investment of less than $2.5 million in a vessel which is 9 years younger, almost twice as large and more flexible commercially." 

After the sale of M/V Anking and the acquisition of M/V Wehr Flottbek, Euroseas Ltd. fleet profile will be as follows:

                         
Name   Type   Dwt   TEU   Year Built   Employment   TCE Rate ($/day)
Dry Bulk Vessels                        
PANTELIS   Panamax   74,020       2000   TC until' Jan-14 + 1 Year Charterer's Option   $11,200 +50/50 Profit Share, $14,200
ELENI P   Panamax   72,119       1997   Baumarine Pool   Spot Earnings since February 2013
IRINI   Panamax   69,734       1988   Open    
ARISTIDES N.P.   Panamax   69,268       1993   TC 'til Feb-14   $7,500
MONICA P   Handymax   46,667       1998   TC'Till Sep-13   $12,375
Total Dry Bulk Vessels   5   331,808                
Container Carriers                        
EVRIDIKI G (ex-MAERSK NOUMEA)   Intermediate   34,677   2,556   2001   TC 'til Apr -14   $8,000
TIGER BRIDGE   Intermediate   31,627   2,228   1990   TC till Nov-13 + 12 Months in Charterers Option   $6,000 $8,000
AGGELIKI P   Intermediate   30,360   2,008   1998   TC till Feb-14   $6,000
DESPINA P   Handy size   33,667   1,932   1990   TC 'til Aug-13   $6,000
CAPTAIN COSTAS(ex-OEL TRANSWORLD)   Handy size   30,007   1,742   1992   TC till Mar-14 12 Months in Charterers Option   $6,500 $11,500
JOANNA   Handy size   22,301   1,738   1999   (to be delivered by end of June-13)    
MARINOS   Handy size   23,596   1,599   1993   TC 'til Aug-13   $6,250
MANOLIS P   Handy size   20,346   1,452   1995   TC 'til Oct-13   $6,750
NINOS   Feeder   18,253   1,169   1990   TC 'til Dec-13   $7,690
KUO HSIUNG   Feeder   18,154   1,169   1993   TC till Feb-14 12 months in Charterers Option   $7,700 $11,500
Total Container Carriers   10   262,988   17,593            
Fleet Grand Total   15   594,796   17,593            
                         
                         

Note: Charter duration indicates the earliest redelivery date.

About Euroseas Ltd. Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 136 years. Euroseas trades on the NASDAQ Global Market under the ticker ESEA since January 31, 2007.

Euroseas operates in the dry cargo, drybulk and container shipping markets. Euroseas' operations are managed by Eurobulk Ltd., an ISO 9001:2008 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.

Following the sale of its multipurpose vessel and addition of a handy size containership, the Company will have a fleet of 15 vessels, including 4 Panamax drybulk carriers and 1 Handymax drybulk carrier, 3 Intermediate containership, 5 Handy size containerships and 2 Feeder containerships. Euroseas 5 drybulk carriers have a total cargo capacity of 331,808 dwt, its 10 containerships have a cargo capacity of 17,593 teu.

Forward-Looking Statement This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events and the Company's growth strategy and measures to implement such strategy; including expected vessel acquisitions and entering into further time charters. Words such as "expects," "intends," "plans," "believes," "anticipates," "hopes," "estimates," and variations of such words and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to changes in the demand for dry bulk vessels and container ships, competitive factors in the market in which the Company operates; risks associated with operations outside the United States; and other factors listed from time to time in the Company's filings with the Securities and Exchange Commission. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Visit our website www.euroseas.gr

Company Contact Tasos Aslidis Chief Financial Officer Euroseas Ltd. 11 Canterbury Lane Watchung, NJ 07069 Tel. (908) 301-9091 E-mail: aha@euroseas.gr Investor Relations / Financial Media Nicolas Bornozis President Capital Link, Inc. 230 Park Avenue, Suite 1536 New York, NY 10169 Tel. (212) 661-7566 E-mail: euroseas@capitallink.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 173

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Rosti Group Expands with Alvi Acquisition

Updated Category News Views 139

Rosti Bets on Expansion with Alvi Buyout Rosti Group just rolled the dice big by swallowing Alvi Group, marking another bold move in the ever-swinging industrial and medical device manufacturing rodeo. Suddenly, we’re talking about a company with roughly 3,000 employees on its roster and a neat EUR 450 million in combined revenue. Don't overlook the power play...

Continue Reading
Stocks Jump Ahead of Critical Inflation Reports

Updated Category News Views 0

Stocks Lift as Wall Street Awaits Inflation Data Every trader's favorite game—speculation—returns as major U.S. stock benchmarks kick off Monday with some gusto. The S&P 500, Nasdaq Composite, Dow Jones Industrial Average, and Russell 2000 all saw gains in the early morning session, signaling positive vibes across the board. Numbers don't lie, folks: The S&P climbed...

Continue Reading
Paul Taubman Takes Helm at Cold Spring Harbor Lab

Updated Category News Views 157

Paul Taubman Steers the Ship at CSHL Here's the buzz coming out of Cold Spring Harbor Lab: they're handing the reins over to Paul Taubman. It's like swapping captains in the middle of the ocean—big shoes need to stay afloat. This place isn't just the playground for science nerds; it's a powerhouse in biomedical research. Now, we've got Taubman, a fella who's been...

Continue Reading
Biond's BND-67 Trial: New Hope Against Tumors

Updated Category News Views 55

Turning Heads with a New Approach in Immunotherapy Right off the bat, let's say something's brewing in the world of cancer treatment, and it's got a promising name: BND-67. We're talking about Biond Biologics, an ambitious Israeli outfit aiming to rewrite the rules with their new kid on the block in immunotherapies. This isn't about business as usual. It's about a fresh...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 359

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 417

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Zabalafin Hydrogel: Promise in Treating Atopic Dermatitis

Updated Category News Views 55

Pioneering a New Path in Dermatology Treatment In the world of dermatology, finding a topical solution that tackles the full spectrum of atopic dermatitis (AD) is as rare as hens' teeth. But here's a twist—in a recent research paper gracing the Journal of Drugs in Dermatology, Alphyn Biologics sheds light on their unique contender, Zabalafin Hydrogel. This ain't your...

Continue Reading
ADC Therapeutics' Q3 2026: Revenue Up, Strategy Shift Impresses

Updated Category News Views 37

Riding the Roller Coaster of Financials Crack open the books, and there's more than meets the eye with ADC Therapeutics this quarter. We're talking a $21 million haul in product revenue—that's nothing to sneeze at. Things are heating up with their balance sheet, thanks to a strategic restructuring that's stretching their cash runway out to 2029. That’s some...

Continue Reading
Tencent Cloud's Edge Platform Shines in New Gartner Report

Updated Category News Views 136

The Breakthrough in Edge Computing Everyone's talking about cloud this and cloud that, but Tencent Cloud is taking things a notch further with its EdgeOne platform. It's not just about storing your files in the sky; it's about having the fastest, most secure delivery possible. Gartner's latest report puts these guys right at the top in their Magic Quadrant for Edge...

Continue Reading

Top 5 Most Recently Viewed Articles

Starwood Property Trust Upsizes $500 Million Sustainability Bonds

Updated Category News Views 188

Starwood Property Trust Expands Private Offering of Bonds Starwood Property Trust, Inc. (NYSE: STWD) has made a significant announcement regarding its latest financial maneuver. The company has priced its private offering, which has now been upsized to an impressive $500 million. This offering involves unsecured senior notes with a fixed interest rate of 6.500% due in...

Continue Reading
Prime Medicine Secures Strong Future with BMS Collaboration

Updated Category News Views 134

Prime Medicine (NASDAQ: PRME) landed a hefty collaboration with Bristol Myers Squibb (NYSE: BMY) back in 2024, worth a cool $110 million. The breakdown? A sweet $55 million upfront payment paired with another $55 million as an equity investment. Now, this kind of cash infusion had traders buzzing—just what they needed to keep the lights on until at least mid-2026. But...

Continue Reading
Enjoy Summer Fun with Truly's Creative Rain Check Program

Updated Category News Views 273

Truly Hard Seltzer Introduces the Innovative Rain Check Program Summer is a season of joy, sunshine, and outdoor gatherings, but unpredictable weather can put a damper on plans. As we approach July, many anticipate pool parties and barbecues. However, with increased rainfall patterns reported in various regions, July 4th celebrations might not go as planned. To help fans...

Continue Reading
Top Cybersecurity Tips to Safeguard Your Holidays

Updated Category News Views 115

Top Cybersecurity Tips for the Holiday Season As the holiday season approaches, it presents a myriad of opportunities for shoppers and cybercriminals alike. KnowBe4, a leader in cybersecurity solutions and training, highlights the need for awareness among consumers. This year, the company announces their top five cybersecurity tips aimed at helping shoppers stay safe and...

Continue Reading
Plaza Retail REIT Welcomes New Leadership with Jason Parravano

Updated Category News Views 183

Plaza Retail REIT Announces New Leadership Plaza Retail REIT has officially communicated an exciting shift in its leadership structure. Jason Parravano will take over the role of President & CEO, succeeding Michael Zakuta, who will remain actively involved with the Trust as a Trustee. This leadership transition signifies Plaza's commitment to continuing its strategic...

Continue Reading